The aim of the current study was to determine the plasma levels of CCL2, CCR2 and the levels of the commonly accepted tumor marker (CA 15-3) in 3 groups: (1) the breast cancer patients group; (2) the benign breast tumor group; and (3) the control group consisting of healthy women. This evidence concerns the gene CCR2 and breast benign neoplasm.